Sensei Biotherapeutics (NASDAQ:SNSE) Shares Up 2.1% – Here’s Why

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) shares were up 2.1% during trading on Wednesday . The company traded as high as $16.52 and last traded at $14.1450. Approximately 219,729 shares changed hands during mid-day trading, an increase of 310% from the average daily volume of 53,599 shares. The stock had previously closed at $13.85.

Analysts Set New Price Targets

SNSE has been the topic of several analyst reports. Citigroup initiated coverage on Sensei Biotherapeutics in a research report on Friday, May 22nd. They set a “buy” rating and a $55.00 price target for the company. BTIG Research assumed coverage on shares of Sensei Biotherapeutics in a research note on Thursday, June 11th. They set a “buy” rating and a $55.00 price objective on the stock. Wall Street Zen cut shares of Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Cantor Fitzgerald reissued an “overweight” rating on shares of Sensei Biotherapeutics in a report on Thursday, June 4th. Finally, Loop Capital set a $50.00 price target on shares of Sensei Biotherapeutics in a research report on Thursday, May 28th. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $48.00.

Sensei Biotherapeutics Stock Up 2.1%

The firm has a market cap of $18.98 million, a price-to-earnings ratio of -0.10 and a beta of -0.25. The company’s 50-day moving average price is $17.27 and its 200-day moving average price is $19.62.

Sensei Biotherapeutics (NASDAQ:SNSE) last released its quarterly earnings results on Friday, May 15th. The company reported ($131.45) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($130.83).

Insider Buying and Selling

In other Sensei Biotherapeutics news, major shareholder James Peyer sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $20.02, for a total transaction of $500,500.00. Following the completion of the sale, the insider directly owned 130,142 shares in the company, valued at approximately $2,605,442.84. The trade was a 16.11% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 7.00% of the company’s stock.

Institutional Trading of Sensei Biotherapeutics

Institutional investors have recently made changes to their positions in the company. Vivo Capital LLC purchased a new stake in shares of Sensei Biotherapeutics during the first quarter worth approximately $22,758,000. Stempoint Capital LP acquired a new position in Sensei Biotherapeutics in the 1st quarter valued at $4,188,000. Bank of America Corp DE raised its stake in Sensei Biotherapeutics by 10,692.5% in the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after purchasing an additional 32,719 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in Sensei Biotherapeutics by 178.2% in the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock valued at $1,010,000 after purchasing an additional 20,525 shares in the last quarter. 10.50% of the stock is owned by institutional investors and hedge funds.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.